UPDATE : Tuesday, August 11, 2020
HOME Pharma
‘Abbvie’s psoriasis drug proves long-term treatment effect’
  • By Shim Hyun-tai
  • Published 2020.06.10 15:59
  • Updated 2020.06.10 15:59
  • comments 0

Abbvie's Skyrizi (ingredient: risankizumab) showed the best treatment efficacy and lasting effect on plaque psoriasis patients among existing biological products, Professor Youn Sang-woong of the Seoul National University Bundang Hospital said Wednesday.

Its duration of the therapeutic effect was also longer than that of other biologicals. Patients only had to visit medical facilities four times a year due to relatively longer half-life than other drugs, Professor Youn said.

Professor Youn Sang-woong of the Seoul National University Bundang Hospital explains the results of the clinical trial on Abbvie’s Skyrizi (ingredient: risankizumab), in an online conference held by Abbvie on Wednesday.

Psoriasis is an autoimmune disease caused by abnormalities in the body's immune function. The most common symptoms are redness of the skin and white dead skin. The goal of the therapy psoriasis patients is to have clean skin and to maintain the effectiveness for a long time.

The pathogenesis of psoriasis has recently been revealed, and biological agents involved in the mechanism have been developed, leading to significant progress in the performance of psoriasis treatment, Youn said.

In a long-term study that compared Skyrizi and Stelara (ingredient: ustekinumab) and Humira (ingredient: adalimumab), researchers confirmed that the proportion of patients who achieved Psoriasis Area Severity Index (PASI) 90 at week 16 of treatment reached 75-90 percent. PASI indicates the treatment effect of psoriasis drugs. In the past, PASI 50 was used as a standard for the treatment effect of tumor necrosis factor inhibitors.

Professor Youn said that patients who achieved PASI 100 with spotless skin were 20-30 percent in the Stelara group. In comparison, the number neared 60 percent in the Skyrizi group.

He added that three years of clinical data is available, and most of the patients who reached PASI 90 and 100 at week 16 remained stable and maintained treatment response.

"A small number of hospitals had used Skyrizi in Korea as it received insurance benefits as recently as June 1," Youn said. "As the doctor who participated in the initial clinical trials on Skyrizi, however, I can say it is an excellent drug among existing biological agents in terms of treatment efficacy and lasting effect."


<© Korea Biomedical Review, All rights reserved.>

Other articles by Shim Hyun-tai
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top